Are current development programs realising the full potential of new agents?
作者信息
Lønning Per Eystein
机构信息
Section of Oncology, Institute of Medicine, University of Bergen, and Department of Oncology, Haukeland University Hospital, N-5021, Bergen, Norway.
出版信息
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S23. doi: 10.1186/bcr2752.
Abstract
摘要
相似文献
1
Are current development programs realising the full potential of new agents?当前的研发项目是否正在充分发挥新药物的全部潜力？
Breast Cancer Res. 2010 Dec 20;12 Suppl 4(Suppl 4):S23. doi: 10.1186/bcr2752.
2
New research on the treatment of small HER2-positive breast cancers.关于小HER2阳性乳腺癌治疗的新研究。
Clin Adv Hematol Oncol. 2014 Feb;12(2):124-7.
3
Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.蛋白质组学作为早期乳腺癌患者个性化辅助化疗的指导
Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90.
4
The triple-negative subtype: new ideas for the poorest prognosis breast cancer.三阴性亚型：针对预后最差的乳腺癌的新见解。
J Natl Cancer Inst Monogr. 2011;2011(43):108-10. doi: 10.1093/jncimonographs/lgr038.
5
Can patients with metastatic breast cancer be cured after introduction of newer and more effective agents?转移性乳腺癌患者在引入更新、更有效的药物后能否被治愈？
Breast Cancer. 2012 Jul;19(3):212-7. doi: 10.1007/s12282-011-0277-2. Epub 2011 Jun 1.
6
[Novel target therapies used in breast cancer management].[用于乳腺癌治疗的新型靶向疗法]
Vopr Onkol. 2011;57(5):592-600.
7
Synthetic Lethality - Its Current Application and Potential in Oncological Treatment.合成致死性——其在肿瘤治疗中的当前应用与潜力
Klin Onkol. 2019 Fall;32(Supplementum 3):19-24. doi: 10.14735/amko20193S.
8
Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.聚（ADP-核糖）聚合酶抑制剂在治疗BRCA突变乳腺癌中的进展。
Clin Adv Hematol Oncol. 2018 Jul;16(7):491-501.
9
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.表皮生长因子受体家族抑制剂在乳腺癌中的治疗作用：现状和未来临床展望。
Med Res Rev. 2012 Jan;32(1):166-215. doi: 10.1002/med.20209. Epub 2010 Oct 25.
10
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.当前的药物研发项目是否正在充分发挥新药物的全部潜力？酪氨酸激酶抑制剂。
Breast Cancer Res. 2009;11 Suppl 3(Suppl 3):S24. doi: 10.1186/bcr2443. Epub 2009 Dec 18.
本文引用的文献
1
Molecular basis for therapy resistance.治疗抵抗的分子基础。
Mol Oncol. 2010 Jun;4(3):284-300. doi: 10.1016/j.molonc.2010.04.005. Epub 2010 Apr 24.
2
Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601).蒽环类药物获益的预测标志物：英国国家表阿霉素辅助试验（NEAT/BR9601）的前瞻性计划分析。
Lancet Oncol. 2010 Mar;11(3):266-74. doi: 10.1016/S1470-2045(10)70006-1. Epub 2010 Jan 13.
3
Complex landscapes of somatic rearrangement in human breast cancer genomes.人类乳腺癌基因组中体细胞重排的复杂景观。
Nature. 2009 Dec 24;462(7276):1005-10. doi: 10.1038/nature08645.
4
Targeted chemotherapy? Platinum in BRCA1-dysfunctional breast cancer.靶向化疗？BRCA1功能失调型乳腺癌中的铂类药物
J Clin Oncol. 2010 Jan 20;28(3):361-3. doi: 10.1200/JCO.2009.24.0838. Epub 2009 Dec 14.
5
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.21 基因复发评分检测在化疗后淋巴结阳性、雌激素受体阳性乳腺癌绝经后妇女中的预后和预测价值：一项随机试验的回顾性分析。
Lancet Oncol. 2010 Jan;11(1):55-65. doi: 10.1016/S1470-2045(09)70314-6. Epub 2009 Dec 10.
6
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.雌激素受体阳性乳腺癌患者中Ki67表达与多西他赛疗效
J Clin Oncol. 2009 Jun 10;27(17):2809-15. doi: 10.1200/JCO.2008.18.2808. Epub 2009 Apr 20.
7
The cancer genome.癌症基因组
Nature. 2009 Apr 9;458(7239):719-24. doi: 10.1038/nature07943.
8
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes.三阴性乳腺癌：区分基底样和非基底样亚型
Clin Cancer Res. 2009 Apr 1;15(7):2302-10. doi: 10.1158/1078-0432.CCR-08-2132. Epub 2009 Mar 24.
9
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.三阴性乳腺癌年轻女性中BRCA1突变的患病率。
BMC Cancer. 2009 Mar 19;9:86. doi: 10.1186/1471-2407-9-86.
10
Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.乳腺癌亚型与淋巴结阳性乳腺癌对多西他赛的反应：BCIRG 001试验中免疫组化定义的应用
J Clin Oncol. 2009 Mar 10;27(8):1168-76. doi: 10.1200/JCO.2008.18.1024. Epub 2009 Feb 9.
Zotero 插件